Dear Editor,
I am writing in response to the opinion piece titled “Patients with severe ME/CFS need hope and expert multidisciplinary care” (BMJ 2025; 389:r977), by Alastair Miller, Fiona Symington, Paul Garner, and Maria Pedersen. While the article attempts to provide a constructive perspective on recovery and care for those with severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), it misrepresents key aspects of the illness and risks perpetuating harmful clinical practices.
ME/CFS is a complex, multi-system biological disease, recognised by the World Health Organization, with growing biomedical evidence implicating immune dysregulation, neurological impairment, and metabolic dysfunction. The article’s framing of ME/CFS as largely driven by maladaptive beliefs and functional dysregulation is outdated, and directly conflicts with the 2021 NICE guidelines, which specifically caution against graded exercise therapy (GET) and other interventions aiming to “recondition” patients or reframe their thinking as a route to recovery.
In severe cases, ME/CFS can cause profound debilitation - bedbound patients often experience hypersensitivity, post-exertional symptom exacerbation, and an inability to tolerate light, sound, or minimal movement. To suggest that these manifestations persist due to unhelpful beliefs or conditioned responses is not only clinically inaccurate but also psychologically damaging. This kind of narrative has long contributed to medical gaslighting, delayed diagnosis, and denial of appropriate care.
The authors also repeat the often-cited estimate that ME/CFS affects 250,000 people in the UK. However, this figure is outdated. A 2024 study from the University of Edinburgh, analysing NHS data across England, identified approximately 404,000 individuals with ME/CFS in England alone - a 62% increase from previous estimates (Pulse Today, 2024 -
https://www.pulsetoday.co.uk/news/clinical-areas/neurology/researchers-f...). This reinforces the urgent need for accurate prevalence data and expanded biomedical services, particularly for severely affected patients, who often receive no specialist care.
While hope is essential, it must be grounded in evidence. Recovery in ME/CFS - especially in severe cases - is rare, and implying that it can be achieved through reframing thoughts or increasing activity contradicts both patient experience and clinical guidelines. It risks causing harm, particularly if it leads clinicians to push treatments that worsen symptoms or invalidate patient experiences.
I respectfully urge The BMJ to ensure that future commentary on ME/CFS is informed by current evidence, respects the lived realities of patients, and does not repeat narratives that have already caused significant harm within the ME/CFS community.
Yours sincerely,
Suzy Evans
West London
Competing interests: No competing interests
14 May 2025
Suzy J Evans
Medically Retired
West London